BeijingChunfengPharmaceuticals Co., Ltd.

Not yet clear

① Analgesic effect: It is a peripheral analgesic by inhibiting the synthesis of prostaglandins and other substances, and may act on the hypothalamus; ② Anti-inflammatory effect: It may work by inhibiting the synthesis of prostaglandins or other inflammatory substances, and the inhibition of the release of lysosomal enzymes and leukocyte chemotaxis may also be related to it; ③ Antipyretic effect: It may act on the hypothalamic temperature regulation center to increase heat dissipation and have an antipyretic effect, which is related to the inhibition of prostaglandin synthesis in the hypothalamus; ④ Anti-rheumatic effect: In addition to antipyretic and analgesic effects, it mainly has anti-inflammatory effects; ⑤ Inhibition of platelet aggregation: It works by inhibiting platelet cyclooxygenase and reducing the production of prostaglandins.

This product has a broad-spectrum antibacterial effect and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, and Gram-negative bacteria such as Haemophilus influenzae, Legionella pneumophila, and Neisseria gonorrhoeae. It also has antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, and Mycoplasma pneumoniae and Chlamydia pneumoniae, but has poor effects on anaerobic bacteria and enterococci. Its mechanism of action is to inhibit the activity of bacterial DNA gyrase, prevent the synthesis and replication of bacterial DNA, and cause bacterial death.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. Its effect on Gram-positive bacteria is slightly worse than that of erythromycin, and its effect on Legionella pneumophila is stronger than that of erythromycin. Its antimicrobial effect on Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P position), blocking the transfer RNA (t-RNA) from binding to the P position, and also blocking the transfer of the polypeptide chain from the acceptor position (A position) to the P position, thereby inhibiting bacterial protein synthesis.

The antibacterial spectrum is the same as that of lincomycin, and the antibacterial activity is 4 to 8 times stronger than that of lincomycin. It has high antibacterial activity against aerobic Gram-positive cocci, such as Staphylococcus (including penicillin-resistant and methicillin-sensitive strains), hemolytic streptococci, grass-green streptococci, and Streptococcus pneumoniae. It also has good antibacterial effects on anaerobic bacteria. Most of the genera, such as Bacteroides, Fusobacterium, Actinomyces, Peptococci, and Peptostreptococci are sensitive to this product. This product acts on the 50S subunit of the ribosome of sensitive bacteria, preventing the extension of the peptide chain, thereby inhibiting the protein synthesis of bacterial cells. It is generally an antibacterial agent, but at high concentrations, it also has a bactericidal effect on certain bacteria.